Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
出版年份 2020 全文链接
标题
Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
作者
关键词
-
出版物
Genes
Volume 11, Issue 9, Pages 1098
出版商
MDPI AG
发表日期
2020-09-21
DOI
10.3390/genes11091098
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)
- (2020) Thomas Cluzeau et al. BLOOD
- CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
- (2020) Beatriz Salvador-Barbero et al. CANCER CELL
- Implementation of systematic genetic counseling (GC) and multigene germline testing (MGT) for pancreatic cancer (PC) patients (pts).
- (2020) Matthew B. Yurgelun et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
- (2020) Eileen M. O’Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN
- (2020) Keith T Flaherty et al. JNCI-Journal of the National Cancer Institute
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
- (2020) Michael J Pishvaian et al. LANCET ONCOLOGY
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
- (2020) Michelle Chan-Seng-Yue et al. NATURE GENETICS
- ATM Serine/Threonine Kinase and its Role in Pancreatic Risk
- (2020) Neha Nanda et al. Genes
- GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
- (2020) Grainne M. O'Kane et al. CLINICAL CANCER RESEARCH
- Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
- (2020) Wungki Park et al. CLINICAL CANCER RESEARCH
- NTRK gene fusions in bilio-pancreatic cancers.
- (2020) Anne Demols et al. JOURNAL OF CLINICAL ONCOLOGY
- CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
- (2020) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
- (2020) M. Patel et al. ANNALS OF ONCOLOGY
- Etiologic Index — A Case-Only Measure of BRCA1/2–Associated Cancer Risk
- (2020) Raymond Hughley et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
- (2020) Yifan Wang et al. CLINICAL CANCER RESEARCH
- BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
- (2020) Marco H Hofmann et al. Cancer Discovery
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting Alterations in the RAF–MEK Pathway
- (2019) Rona Yaeger et al. Cancer Discovery
- Real-time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations that Might be Targeted with Existing Drugs or Used as Biomarkers
- (2019) Aatur D. Singhi et al. GASTROENTEROLOGY
- Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with implementation of point of care (POC) testing.
- (2019) Heather Symecko et al. JOURNAL OF CLINICAL ONCOLOGY
- Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood
- (2019) Maryam A. L. Eissa et al. Clinical Epigenetics
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer
- (2019) S.B. Dreyer et al. CLINICAL ONCOLOGY
- Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis
- (2019) Francesco Natale et al. Clinical Epigenetics
- Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma
- (2019) Robert P. Jones et al. JAMA Surgery
- Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma
- (2019) Yao-Yu Hsieh et al. Genes
- Identifying patients with NTRK fusion cancer
- (2019) J P Solomon et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
- (2019) R. Govindan et al. Journal of Thoracic Oncology
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
- (2019) Marina Ayres Pereira et al. Genes
- Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers’ Discovery
- (2019) Mariarita Brancaccio et al. Genes
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
- (2018) Zishuo I. Hu et al. CLINICAL CANCER RESEARCH
- Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models
- (2018) Talia Golan et al. INTERNATIONAL JOURNAL OF CANCER
- Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
- (2018) Chunling Hu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
- (2018) Matteo Allegretti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
- (2018) Maeve A Lowery et al. JNCI-Journal of the National Cancer Institute
- Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
- (2018) Luc Gailhouste et al. Cell Death & Disease
- Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
- (2018) Gwen Lomberk et al. Nature Communications
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
- (2018) Maeve A Lowery et al. JNCI-Journal of the National Cancer Institute
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program
- (2018) Andrea Eisen et al. Molecular Genetics & Genomic Medicine
- Clinical performance pilot using cognitive computing for clinical trial matching at Mayo Clinic.
- (2018) Jane Helgeson et al. JOURNAL OF CLINICAL ONCOLOGY
- Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.
- (2018) Tanya Skamene et al. JOURNAL OF CLINICAL ONCOLOGY
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
- (2018) Davide Melisi et al. BRITISH JOURNAL OF CANCER
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
- (2018) Francesco Schettini et al. Frontiers in Oncology
- Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
- (2017) Lawrence J. Jennings et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
- (2017) Marilyn M. Li et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
- (2017) Paz Polak et al. NATURE GENETICS
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience
- (2017) Todd C. Knepper et al. ONCOLOGIST
- Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing
- (2017) Nirali M. Patel et al. ONCOLOGIST
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
- (2017) Jonathan M. Yingling et al. Oncotarget
- Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
- (2017) Rémy Nicolle et al. Cell Reports
- Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
- (2017) Ashton A. Connor et al. JAMA Oncology
- KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
- (2017) Jonas Cicenas et al. Cancers
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
- (2016) F. Meric-Bernstam et al. ANNALS OF ONCOLOGY
- DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster
- (2016) S. Zagorac et al. CANCER RESEARCH
- GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
- (2016) Paola Martinelli et al. GUT
- The role of neoantigens in response to immune checkpoint blockade
- (2016) Nadeem Riaz et al. INTERNATIONAL IMMUNOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Familial pancreatic cancer
- (2016) Gloria M. Petersen SEMINARS IN ONCOLOGY
- The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
- (2016) Jiandong Chen Cold Spring Harbor Perspectives in Medicine
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
- (2016) Kasmintan A. Schrader et al. JAMA Oncology
- Current practices and guidelines for clinical next-generation sequencing oncology testing
- (2016) Samuel P. Strom et al. Cancer Biology & Medicine
- Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673
- (2015) Alexandra-Zoe Andrei et al. CANCER LETTERS
- KRAS as a Therapeutic Target
- (2015) F. McCormick CLINICAL CANCER RESEARCH
- Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec
- (2015) A.L. Smith et al. Current Oncology
- Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer
- (2015) Robert C. Grant et al. GASTROENTEROLOGY
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
- (2015) Spring Holter et al. JOURNAL OF CLINICAL ONCOLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
- (2015) Richard A Moffitt et al. NATURE GENETICS
- All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health
- (2015) M. Lawler et al. Cancer Discovery
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Cancers associated withBRCA1andBRCA2mutations other than breast and ovarian
- (2014) Jacqueline Mersch et al. CANCER
- The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings
- (2014) Maryam Shabihkhani et al. CLINICAL BIOCHEMISTRY
- More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling
- (2013) Aisha S. Sie et al. Familial Cancer
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer
- (2013) Angela Chou et al. Genome Medicine
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Effort Required in Eligibility Screening for Clinical Trials
- (2012) Lynne T. Penberthy et al. Journal of Oncology Practice
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic cancerDNMT1expression and sensitivity toDNMT1inhibitors
- (2010) Ang Li et al. CANCER BIOLOGY & THERAPY
- Risk of Pancreatic Cancer in Families With Lynch Syndrome
- (2009) Fay Kastrinos JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Homologous recombination in DNA repair and DNA damage tolerance
- (2008) Xuan Li et al. CELL RESEARCH
- BRCAGermline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
- (2008) Cristina R. Ferrone et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas
- (2008) Seung-Mo Hong et al. MODERN PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now